Premier Biomedical, Inc.
BIEI
$0.00
$0.000.00%
OTC PK
| 12/31/2019 | 09/30/2019 | ||||
|---|---|---|---|---|---|
| Revenue | -62.86% | -7.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -62.86% | -7.89% | |||
| Cost of Revenue | 335.29% | -5.56% | |||
| Gross Profit | -438.89% | -10.00% | |||
| SG&A Expenses | 52.11% | -11.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 59.41% | -11.34% | |||
| Operating Income | -65.63% | 11.39% | |||
| Income Before Tax | 81.11% | 20.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 81.11% | 20.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.11% | 20.00% | |||
| EBIT | -65.63% | 11.39% | |||
| EBITDA | -66.77% | 11.63% | |||
| EPS Basic | 97.06% | 69.51% | |||
| Normalized Basic EPS | 97.62% | 69.78% | |||
| EPS Diluted | 95.00% | 55.16% | |||
| Normalized Diluted EPS | 97.62% | 69.78% | |||
| Average Basic Shares Outstanding | 515.64% | 163.16% | |||
| Average Diluted Shares Outstanding | 515.64% | 163.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||